PortfoliosLab logoPortfoliosLab logo
DNA vs. PANW
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

DNA vs. PANW - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ginkgo Bioworks Holdings, Inc. (DNA) and Palo Alto Networks, Inc. (PANW). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, DNA achieves a -5.05% return, which is significantly lower than PANW's 51.80% return.


DNA

1D
-1.38%
1M
2.33%
YTD
-5.05%
6M
-15.52%
1Y
-11.74%
3Y*
-53.33%
5Y*
-54.41%
10Y*

PANW

1D
0.03%
1M
15.15%
YTD
51.80%
6M
45.87%
1Y
42.47%
3Y*
33.77%
5Y*
35.61%
10Y*
29.12%
*Multi-year figures are annualized to reflect compound growth (CAGR)

DNA vs. PANW - Yearly Performance Comparison


2026 (YTD)20252024202320222021
DNA
Ginkgo Bioworks Holdings, Inc.
-5.05%-15.38%-85.47%0.00%-79.66%-21.68%
PANW
Palo Alto Networks, Inc.
51.80%1.23%23.41%111.32%-24.81%51.85%

Correlation

The correlation between DNA and PANW is 0.16, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.16

Correlation (3Y)
Calculated over the trailing 3-year period

0.20

Correlation (5Y)
Calculated over the trailing 5-year period

0.28

Correlation (All Time)
Calculated using the full available price history since Apr 19, 2021

0.28

The correlation between DNA and PANW shifts across timeframes, from 0.16 (1 year) to 0.28 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

DNA:

$469.96M

PANW:

$208.04B

EPS

DNA:

-$5.40

PANW:

$1.17

PS Ratio

DNA:

3.65

PANW:

18.95

PB Ratio

DNA:

1.06

PANW:

7.52

Total Revenue (TTM)

DNA:

$121.84M

PANW:

$10.61B

Gross Profit (TTM)

DNA:

$99.27M

PANW:

$7.63B

EBITDA (TTM)

DNA:

-$218.90M

PANW:

$1.33B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

DNA vs. PANW — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DNA
DNA Risk / Return Rank: 3939
Overall Rank
DNA Sharpe Ratio Rank: 3636
Sharpe Ratio Rank
DNA Sortino Ratio Rank: 4343
Sortino Ratio Rank
DNA Omega Ratio Rank: 4343
Omega Ratio Rank
DNA Calmar Ratio Rank: 3636
Calmar Ratio Rank
DNA Martin Ratio Rank: 3636
Martin Ratio Rank

PANW
PANW Risk / Return Rank: 6969
Overall Rank
PANW Sharpe Ratio Rank: 7575
Sharpe Ratio Rank
PANW Sortino Ratio Rank: 6969
Sortino Ratio Rank
PANW Omega Ratio Rank: 7070
Omega Ratio Rank
PANW Calmar Ratio Rank: 6666
Calmar Ratio Rank
PANW Martin Ratio Rank: 6666
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DNA vs. PANW - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Ginkgo Bioworks Holdings, Inc. (DNA) and Palo Alto Networks, Inc. (PANW). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


DNAPANWDifference
Sharpe ratioReturn per unit of total volatility

-1.23

Sortino ratioReturn per unit of downside risk

-1.10

Omega ratioGain probability vs. loss probability

1.06

1.21

-0.15

Calmar ratioReturn relative to maximum drawdown

-0.23

1.16

-1.39

Martin ratioReturn relative to average drawdown

-0.39

2.62

-3.01

DNA vs. PANW - Sharpe Ratio Comparison

The current DNA Sharpe Ratio is -0.16, which is lower than the PANW Sharpe Ratio of 1.07. The chart below compares the historical Sharpe Ratios of DNA and PANW, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

DNA vs. PANW - Drawdown Comparison

The maximum DNA drawdown since its inception was -99.10%, which is greater than PANW's maximum drawdown of -47.98%. Use the drawdown chart below to compare losses from any high point for DNA and PANW.


Loading charts...

Drawdown Indicators


DNAPANWDifference

Max Drawdown

Largest peak-to-trough decline

-99.10%

-47.98%

-51.12%

Max Drawdown (1Y)

Largest decline over 1 year

-66.05%

-36.01%

-30.04%

Max Drawdown (3Y)

Largest decline over 3 years

-94.72%

-36.01%

-58.71%

Max Drawdown (5Y)

Largest decline over 5 years

-99.10%

-36.01%

-63.09%

Max Drawdown (10Y)

Largest decline over 10 years

-47.98%

Current Drawdown

Current decline from peak

-98.68%

-6.94%

-91.74%

Average Drawdown

Average peak-to-trough decline

-79.88%

-14.68%

-65.20%

Ulcer Index

Depth and duration of drawdowns from previous peaks

39.10%

15.87%

+23.23%

Volatility

DNA vs. PANW - Volatility Comparison

Ginkgo Bioworks Holdings, Inc. (DNA) has a higher volatility of 21.11% compared to Palo Alto Networks, Inc. (PANW) at 16.97%. This indicates that DNA's price experiences larger fluctuations and is considered to be riskier than PANW based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


DNAPANWDifference

Volatility (1M)

Calculated over the trailing 1-month period

21.11%

16.97%

+4.14%

Volatility (6M)

Calculated over the trailing 6-month period

70.92%

32.33%

+38.59%

Volatility (1Y)

Calculated over the trailing 1-year period

97.64%

38.96%

+58.68%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

97.78%

41.72%

+56.06%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

96.33%

38.62%

+57.71%

Dividends

DNA vs. PANW - Dividend Comparison

Neither DNA nor PANW has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

DNA vs. PANW - Financials Comparison

This section allows you to compare key financial metrics between Ginkgo Bioworks Holdings, Inc. and Palo Alto Networks, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00500.00M1.00B1.50B2.00B2.50B3.00B3.50B202220232024202520260
3.00B
(DNA) Total Revenue
(PANW) Total Revenue
Values in USD except per share items

Frequently Asked Questions


DNA and PANW have a correlation of 0.16, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

DNA has higher volatility (21.11%) compared to PANW (16.97%). In terms of maximum drawdown, DNA dropped -99.10% vs PANW's -47.98%.

PANW currently has the higher Sharpe Ratio (1.07 vs -0.16), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for DNA and PANW

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer